UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)
1.3300 x 10 1.3800 x 2
Post-market by (Cboe BZX)
1.3300 -0.0400 (-2.92%) 04/23/25 [NASDAQ]
1.3300 x 10 1.3800 x 2
Post-market 1.3300 unch (unch) 16:02 ET
Quote Overview for Wed, Apr 23rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.3300
Day High
1.4900
Open 1.4199
Previous Close 1.3700 1.3700
Volume 2,159,305 2,159,305
Avg Vol 2,496,350 2,496,350
Stochastic %K 84.97% 84.97%
Weighted Alpha -70.74 -70.74
5-Day Change +0.2100 (+18.75%) +0.2100 (+18.75%)
52-Week Range 0.6611 - 5.9200 0.6611 - 5.9200
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 157,007
  • Shares Outstanding, K 114,604
  • Annual Sales, $ 13,630 K
  • Annual Income, $ -186,260 K
  • EBIT $ -196 M
  • EBITDA $ -186 M
  • 60-Month Beta 2.41
  • Price/Sales 10.51
  • Price/Cash Flow N/A
  • Price/Book 0.45

Options Overview Details

View History
  • Implied Volatility 333.46% ( -1.58%)
  • Historical Volatility 125.29%
  • IV Percentile 93%
  • IV Rank 60.74%
  • IV High 541.64% on 12/12/24
  • IV Low 11.45% on 09/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 211
  • Volume Avg (30-Day) 213
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 7,590
  • Open Int (30-Day) 5,781

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.39
  • Number of Estimates 5
  • High Estimate -0.31
  • Low Estimate -0.45
  • Prior Year -0.47
  • Growth Rate Est. (year over year) +17.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6611 +101.18%
on 04/04/25
Period Open: 0.9139
1.4900 -10.74%
on 04/23/25
+0.4161 (+45.53%)
since 03/21/25
3-Month
0.6611 +101.18%
on 04/04/25
Period Open: 1.3400
1.8100 -26.52%
on 02/19/25
-0.0100 (-0.75%)
since 01/23/25
52-Week
0.6611 +101.18%
on 04/04/25
Period Open: 4.5400
5.9200 -77.53%
on 07/26/24
-3.2100 (-70.70%)
since 04/23/24

Most Recent Stories

More News
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag

Fate Therapeutics FATE recently announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational pipeline candidate FT819 for the treatment of active...

KRYS : 165.80 (-1.78%)
JAZZ : 104.19 (+0.78%)
ADMA : 21.73 (+1.59%)
FATE : 1.3300 (-2.92%)
Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic

CEO Bob Valamehr said the RMAT designation recognises the therapy's potential in treating lupus.

VTI : 263.44 (+1.70%)
FATE : 1.3300 (-2.92%)
IWM : 190.25 (+1.48%)
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

FATE : 1.3300 (-2.92%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

FATE : 1.3300 (-2.92%)
From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As cancer rates continue to climb worldwide, the push for innovative treatments has never been more...

ALLO : 1.6100 (+1.26%)
ONCY : 0.5666 (-5.57%)
TARA : 4.20 (+6.60%)
YMAB : 4.12 (-3.29%)
FATE : 1.3300 (-2.92%)
ONC.TO : 0.79 (-5.95%)
Fate Therapeutics: Q4 Earnings Snapshot

Fate Therapeutics: Q4 Earnings Snapshot

FATE : 1.3300 (-2.92%)
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

FATE : 1.3300 (-2.92%)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

FATE : 1.3300 (-2.92%)
Fate Therapeutics to Present at Upcoming Investor Conferences

FATE : 1.3300 (-2.92%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

FATE : 1.3300 (-2.92%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

FATE : 1.3300 (-2.92%)
Fate Therapeutics Reports Positive Phase 1 Results for FT819 in Lupus Treatment with Favorable Safety Profile and Initiates Dose Expansion

Fate Therapeutics reports positive results from FT819 study in lupus, showing effective B-cell depletion and favorable safety outcomes.Quiver AI SummaryFate Therapeutics, Inc. announced promising results...

FATE : 1.3300 (-2.92%)
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

FATE : 1.3300 (-2.92%)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

FATE : 1.3300 (-2.92%)
Fate Therapeutics Announces Leadership Transition as Bob Valamehr, Ph.D. MBA, to Succeed Scott Wolchko as President and CEO Effective January 1, 2025

Bob Valamehr will become CEO of Fate Therapeutics on January 1, 2025, succeeding retiring Scott Wolchko.Quiver AI SummaryFate Therapeutics, a clinical-stage biopharmaceutical company focused on induced...

FATE : 1.3300 (-2.92%)
Fate Therapeutics Announces Leadership Transition

FATE : 1.3300 (-2.92%)
Fate Therapeutics to Present at Upcoming December Investor Conferences

FATE : 1.3300 (-2.92%)
FATE Presents Encourgaing Data From Lupus Study, Stock Gains

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate  FT819.Data showed...

IMCR : 29.80 (+0.95%)
CSTL : 21.27 (-3.23%)
FATE : 1.3300 (-2.92%)
SPRO : 0.7271 (-0.70%)
Fate Therapeutics Reports Successful Clinical Remission in First Patient Treated with FT819 for Lupus Nephritis

A lupus nephritis patient achieved clinical remission after FT819 treatment, showing promising safety and immune reset outcomes. Quiver AI SummaryFate Therapeutics, Inc. announced promising results from...

FATE : 1.3300 (-2.92%)
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

FATE : 1.3300 (-2.92%)

Business Summary

Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.' The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the...

See More

Key Turning Points

3rd Resistance Point 1.6000
2nd Resistance Point 1.5100
1st Resistance Point 1.4400
Last Price 1.3300
1st Support Level 1.2800
2nd Support Level 1.1900
3rd Support Level 1.1200

See More

52-Week High 5.9200
Fibonacci 61.8% 3.9111
Fibonacci 50% 3.2905
Fibonacci 38.2% 2.6700
Last Price 1.3300
52-Week Low 0.6611

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective